Trials / Recruiting
RecruitingNCT05080010
Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma
Three Cycles of Adjuvant Chemotherapy for the Patients With High-risk Retinoblastoma After Enucleation: Prospective Study
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 500 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effect of 3 cycles of chemotherapy(CEV) in the treatment of Stage I enucleated retinoblastoma.
Detailed description
This study will be a phase Ⅲ open label interventional case series. Patients with Stage I enucleated retinoblastoma will receive 3 cycles of chemotherapy(CEV) oon a monthly basis. Patients will be followed for 60 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 3 cycles chemotherapy | Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months. |
Timeline
- Start date
- 2020-11-01
- Primary completion
- 2030-12-31
- Completion
- 2030-12-31
- First posted
- 2021-10-15
- Last updated
- 2021-10-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05080010. Inclusion in this directory is not an endorsement.